Alexion Pharmaceuticals Inc. (ALXN) Reports Fourth Quarter And Full Year 2013 Results And Provides Financial Guidance For 2014
1/30/2014 8:55:22 AM
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31, 2013, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported net product sales of Soliris® (eculizumab) of $441.9 million, compared to $320.5 million for the same period in 2012.
Help employers find you! Check out all the jobs and post your resume.
comments powered by